Weighted Siamese Network to Predict the Time to Onset of Alzheimer's Disease from MRI Images

Alzheimer's Disease (AD), which is the most common cause of dementia, is a progressive disease preceded by Mild Cognitive Impairment (MCI). Early detection of the disease is crucial for making treatment decisions. However, most of the literature on computer-assisted detection of AD focuses on classifying brain images into one of three major categories: healthy, MCI, and AD; or categorising MCI patients into one of (1) progressive: those who progress from MCI to AD at a future examination time during a given study period, and (2) stable: those who stay as MCI and never progress to AD. This misses the opportunity to accurately identify the trajectory of progressive MCI patients. In this paper, we revisit the brain image classification task for AD identification and re-frame it as an ordinal classification task to predict how close a patient is to the severe AD stage. To this end, we select progressive MCI patients from the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset and construct an ordinal dataset with a prediction target that indicates the time to progression to AD. We train a siamese network model to predict the time to onset of AD based on MRI brain images. We also propose a weighted variety of siamese networks and compare its performance to a baseline model. Our evaluations show that incorporating a weighting factor to siamese networks brings considerable performance gain at predicting how close input brain MRI images are to progressing to AD

Disrupted Superior Collicular Activity May Reveal Cervical Dystonia Disease Pathomechanisms

Cervical dystonia is a common neurological movement disorder characterised by muscle contractions causing abnormal movements and postures affecting the head and neck. The neural networks underpinning this condition are incompletely understood. While animal models suggest a role for the superior colliculus in its pathophysiology, this link has yet to be established in humans. The present experiment was designed to test the hypothesis that disrupted superior collicular processing is evident in affected patients and in relatives harbouring a disease-specific endophenotype (abnormal temporal discrimination). The study participants were 16 cervical dystonia patients, 16 unaffected first-degree relatives with abnormal temporal discrimination, 16 unaffected first-degree relatives with normal temporal discrimination and 16 healthy controls. The response of participant’s superior colliculi to looming stimuli was assessed by functional magnetic resonance imaging. Cervical dystonia patients and relatives with abnormal temporal discrimination demonstrated (i) significantly reduced superior collicular activation for whole brain and region of interest analysis; (ii) a statistically significant negative correlation between temporal discrimination threshold and superior collicular peak values. Our results support the hypothesis that disrupted superior collicular processing is involved in the pathogenesis of cervical dystonia. These findings, which align with animal models of cervical dystonia, shed new light on pathomechanisms in humans

FDG PET/CT in Clinical OncologyCase Based Approach with Teaching Points /

XIV, 453 p. 113 illus., 108 illus. in color.onlin

Vascular findings on FDG PET/CT:a pictorial review

Since its introduction into clinical practice, 2-deoxy-2-[(18)F]flu-D-glucose (FDG) positron emission tomography/computed tomography (PET/CT) has become firmly established in the field of oncological imaging, with a growing body of evidence demonstrating its use in infectious and inflammatory vascular pathologies. This pictorial review illustrates the utility of FDG PET/CT as a diagnostic tool in the investigation of vascular disease and highlights some of the more common incidental vascular findings that PET reporters may encounter on standard oncology FDG PET/CTs, including atherosclerosis, large vessel vasculitis, complications of vascular grafts, infectious aortitis and acute aortic syndromes

Effects of vitamin D3 in clinically isolated syndrome and healthy control participants: A double-blind randomised controlled trial

Background: Lowserum vitamin D levels are associated with susceptibility to, and severity of, multiple sclerosis. High dose vitamin D has been proposed as a potential immunomodulator in multiple sclerosis. Objectives: We performed a single centre, investigator-led, exploratory, double-blind, randomised, placebo controlled, trial of vitamin D3 in clinically isolated syndrome and healthy control participants to assess its immunological effects. Secondary end-points included clinical and magnetic resonance imaging outcomes and safety. Methods: Clinically isolated syndrome patients and healthy control participants were randomised to: placebo, 5000 IU or 10,000 IU vitamin D3/day (Vigantol oil). Study duration was 24 weeks. Results: The trial did not meet its primary end point, with no difference in the frequency of proinflammatory CD4þ T cells (interleukin (IL)-17þ/interferon (IFN)-gþ) seen. A higher level of disease freedom (67% versus 50%) was seen in those with serum 1,25 (OH) vitamin D levels>100 nmol/l but this did not reach significance. High dose vitamin D3 was well tolerated with no safety signal. Conclusions: High dose vitamin D3 over 24 weeks was well tolerated but without immunological, magnetic resonance imaging or clinical evidence of benefit. The hypothesised therapeutic effects in clinically isolated syndrome or multiple sclerosis patients may require longer periods of administration or may only be seen in patients treated with vitamin D3 as an adjunct to established disease modifying therapies